Story perspectives

Ocular Therapeutix Reports Promising AMD Trial Results Despite Stock Drop

2/17/2026

Summary

Story summary

Ocular Therapeutix, Inc. announced Phase 3 SOL-1 results for Axpaxli in wet AMD, with 74.1% maintaining visual acuity at 36 weeks vs 55.8% on Eylea.
The company plans to submit data to the U.S. Food and Drug Administration (FDA) for approval to compete with Eylea, which generated $2.75 billion in sales in 2025.
Nevertheless, Ocular Therapeutix stock fell 25% due to narrower durability differences.
Analysts see potential in ongoing trials despite the market reaction.

1 of 1

Story summary

Ocular Therapeutix, Inc. announced Phase 3 SOL-1 results for Axpaxli in wet AMD, with 74.1% maintaining visual acuity at 36 weeks vs 55.8% on Eylea.
The company plans to submit data to the U.S. Food and Drug Administration (FDA) for approval to compete with Eylea, which generated $2.75 billion in sales in 2025.
Nevertheless, Ocular Therapeutix stock fell 25% due to narrower durability differences.
Analysts see potential in ongoing trials despite the market reaction.